HealthWarehouse.com goes back in the black as B2B growth lifts sales in 2025
HealthWarehouse.com posted a 46% revenue surge to $49M in 2025, driven by an 87% spike in B2B prescription fulfillment — almost entirely fueled by compounded GLP-1 medications. But the growth story has a hard expiration date: the company lost its authority to dispense high-value compounded GLP-1s in late 2025, Q4 revenue cratered 28.1% to $9.9M, and management is warning 2026 results will take a significant hit. Direct-to-consumer prescription sales fell 24.3% as branded drug demand softened and competition intensified, signaling structural pressure on the DTC pharmacy channel heading into 2026.
The real signal here isn't HealthWarehouse's P&L — it's what the GLP-1 compounding shutdown tells you about the broader supplement, weight management, and OTC adjacency market on Amazon and Walmart.
The FDA's crackdown on compounded semaglutide effectively wiped out a $15M+ revenue line overnight for this operator, and the same regulatory risk applies to any seller in weight loss, appetite suppression, or metabolic health categories who built catalog depth around compounding-adjacent claims.
Gross margin compression from 42% to 35% while scaling revenue is the playbook warning: B2B volume growth without pricing power destroys unit economics fast.
A $10M/year Amazon seller in the health category should pull their supplement catalog this Monday and flag any ASIN with GLP-1, semaglutide, or compounding-adjacent claims in the title or bullets — Amazon suppression risk on these listings is elevated as the FDA enforcement wave spreads to marketplace channels.
This story is a preview of what happens when a marketplace revenue strategy is built on regulatory arbitrage — compounded GLP-1s were a legal gray zone, and the FDA closed it. For marketplace operators in health and wellness, 2026 is the year regulatory tightening becomes a first-order P&L risk, not a compliance footnote.
The broader trend: as GLP-1 drugs go fully branded and prescription-gated, a massive consumer demand signal will redirect toward OTC metabolic, appetite, and lifestyle products on Amazon and Walmart — the operators who have clean, compliant catalog positioning in those adjacencies will capture the demand wave; those still clinging to quasi-pharmaceutical claim language will face suppression and ad account risk at the worst possible time.
Pull your Amazon Brand Analytics search term report for the past 90 days and filter for terms including 'GLP-1,' 'semaglutide,' 'weight loss injection,' and 'compounded' — if any of your ASINs are indexing on these terms, run a listing audit this week and remove claim language before an Amazon policy flag triggers suppression or account-level review.
On Walmart Marketplace and Amazon, check your OTC weight management and appetite supplement category rank trends in Seller Central and Walmart Seller Center right now — if velocity has dropped more than 15% in the past 30 days, this signals the GLP-1 demand pullback is already eroding adjacent category searches and you need to reallocate PPC budget away from those ASINs before you burn more ad spend on declining demand.
In the next 30-60 days, expect branded GLP-1 manufacturers (Novo Nordisk, Eli Lilly) to increase DTC and marketplace channel investment as compounding alternatives dry up — position your health brand now by building content and PPC around 'GLP-1 support,' 'metabolic health,' and 'weight management tools' to capture the search demand shift from prescription alternatives toward OTC complement products.
Bottom Line
The GLP-1 compounding ban just vaporized $15M in revenue overnight — your supplement catalog has the same regulatory trap if you don't audit it today.
Source Lens
Analyst Intelligence
Research or editorial analysis that adds market context beyond the official announcement.
Impact Level
medium
The GLP-1 compounding ban just vaporized $15M in revenue overnight — your supplement catalog has the same regulatory trap if you don't audit it today.
Key Stat / Trigger
87% rise in GLP-1 prescription fulfillment revenue driving $49M total 2025 sales — followed by 28.1% Q4 revenue collapse after compounding authority ended
Focus on the operational implication, not just the headline.
Full Coverage
HealthWarehouse. com Inc. returned to profitability in 2025 as robust growth in its business-to-business prescription segment drove a 46% increase in revenue. However, the company said changes in the GLP-1 drug market will weigh on results in 2026. The online pharmacy reported net sales of $49. 0 million for the year ended Dec. 31, up from $33.
6 million in 2024. The increase was driven primarily by an 87% rise in partner services prescription revenue tied to fulfillment of branded and compounded GLP-1 medications. HealthWarehouse. com ranks No. 1,121 in the Top 2000 Database. The Top 2000 ranks North America’s largest online retailers by their annual ecommerce sales. HealthWarehouse.
com’s turnaround in 2025 HealthWarehouse. com’s net income totaled $265,000 in its fiscal full year, compared with a net loss of $333,000 a year earlier. “2025 was a record year for total sales and prescriptions processed, while generating record cash from operations,” said CEO Joseph Peters. Prescription sales increased 49. 3% year over year to $46.
2 million and accounted for most of the company’s revenue growth. The gains reflect expansion in partner services, where HealthWarehouse fulfills prescriptions for business customers. Direct-to-consumer prescription sales declined 24. 3% in 2025, reflecting lower demand for higher-cost branded drugs and increased competition. Over-the-counter sales rose 15.
9% to $2. 5 million, supported by higher marketplace sales. B2B sales and margins for HealthWarehouse. com The shift toward B2B sales pressured margins. Gross margin declined to 35. 0% from 42. 0% in 2024, as higher-cost GLP-1 medications and pricing competition reduced profitability. Cost of sales increased 63. 4% to $31.
9 million, reflecting higher volumes of expensive prescription drugs. Selling, general and administrative expenses increased 17. 7% to $16. 7 million but declined to 34. 1% of sales from 42. 3% a year earlier, indicating improved operating leverage.
The company cited higher order volumes as driving increases in shipping, labor, technology and marketing costs. Fourth-quarter performance weakened as demand for compounded GLP-1 medications slowed. Net sales fell 28. 1% to $9. 9 million, and the company reported a net loss of $69,000, compared with net income of $189,000 in the same period a year earlier.
Prescription sales declined 31. 0% in the quarter across both B2B and direct-to-consumer channels. Adjusted earnings before interest, taxes, depreciation and amortization fell to $189,000 from $523,000. Future of GLP-1 products at HealthWarehouse. com HealthWarehouse.
com said its authority to dispense certain high-value compounded GLP-1 medications ended in 2025, a development expected to significantly affect sales in 2026 until the company replaces that volume through new partners and product offerings. The company said it expects to remain cash-flow positive in 2026 and is focused on expanding its partner pipeline.
HealthWarehouse. com operates a nationwide online pharmacy serving all 50 states and is accredited as an approved digital pharmacy by the National Association of Boards of Pharmacy. Sign up Sign up for a complimentary subscription to Digital Commerce 360 B2B News. It covers technology and business trends in the growing B2B ecommerce industry.
Contact Mark Brohan, senior vice president of B2B and Market Research, at mark@digitalcommerce360. com. Follow him on Twitter @markbrohan. Follow us on LinkedIn, X (formerly Twitter), Facebook and YouTube. Favorite
Original Source
This briefing is based on reporting from Digital Commerce 360. Use the original post for full primary-source context.
Style
Audience